Part 2 scientific research disclosure

Editorial approval scope: The team checked current source fidelity, scope boundaries, dates, arithmetic, reader usefulness, practical workflow, and general-information limitations.

The discloser makes a documented determination

42 CFR 2.52 assigns the decision to the director, managing director, chief-executive-equivalent person, or designee of the Part 2 program or other lawful holder. Verify the decision-maker's delegation, recipient, project, data, purpose, documentation, and applicable regulatory category.

Create a research intake record with discloser identity and status, authorized leader, delegation source, investigator and institution, protocol, funding and sponsor, question, population, data elements, dates, identifiers, transfer, environment, linkage, outputs, retention, destruction, and downstream participants. Preserve the approved protocol and exact decision rather than relying on an email saying a study is cleared.

The leader's determination should follow documented privacy, compliance, research, security, and legal review. A signature by someone senior does not cure missing recipient evidence or an unsupported data request.

Recipient qualification follows named research frameworks

Depending on the parties, the recipient may be a HIPAA covered entity or business associate with documented authorization or waiver, subject to HHS human-subject protections with compliance or exemption documentation, subject to FDA human-subject rules, or a qualifying combination. The exact pathway needs evidence.

Verify the institution and investigator against the materials supplied. Match protocol number, title, approval or exemption, effective dates, sites, personnel, population, data set, purpose, and conditions. Identify whether an IRB, privacy board, human-research protection office, FDA-regulated study, or another named framework supports the project and which records prove it.

Do not treat an academic affiliation, publication plan, IRB submission, data-use agreement, “minimal risk” statement, or researcher credential as interchangeable with the required pathway. Hold expired, mismatched, conditional, or incomplete evidence until the proper body or qualified owner resolves it.

HIPAA status changes the analysis

When the Part 2 program or lawful holder is a HIPAA covered entity or business associate, the use or disclosure follows 45 CFR 164.512(i). If the rule's recipient or discloser conditions do not apply, 42 CFR 2.52 states that the section does not apply. Seek another valid authority or withhold the data.

Document HIPAA status, research authorization or waiver, minimum-necessary or approved data-set analysis, accounting implications where applicable, business-associate limits, and security terms. State law, consent, professional duties, tribal law, certificates or assurances, contracts, and protocol conditions may add protections.

Minimize and control the data set

Map every requested field to a protocol purpose and approved cohort. Separate direct identifiers, dates, diagnoses, treatment, counseling notes, free text, claims, provider data, contact details, linkage keys, and derived variables. Prefer less identifiable information when it can answer the question and record why any patient-identifying field is needed.

Build the extract from controlled source logic, then validate patient identity, Part 2 status, cohort, fields, dates, duplicates, exclusions, and recipient. Preserve query version, candidate count, final count, rejected records, manifest, checksum, approver, destination, and delivery evidence.

Bind the recipient before transfer

Put Part 2 use, redisclosure, reporting, de-identification, security, legal-demand, linkage, retention, destruction, incident, subcontractor, and closure duties into approved agreements and operational controls. Confirm the secure environment, named users, access dates, export rules, output review, and incident route before data moves.

Amendments, new sites, new staff, new variables, linkage, secondary analysis, renewed funding, protocol expiry, publication, or changed storage require re-review. Scheduled transfers should stop when any approval or agreement expires.

Close or correct the project

At study end, reconcile data copies, linkage files, exports, reports, retention duties, destruction, residual access, and legal holds. If data exceeded the approved cohort or reached an unsupported recipient, preserve evidence, contain access, and route privacy, security, research, legal, clinical, and patient communication decisions.

Example with research proposals

Twelve proposals request identifiable data. Nine contain the required recipient and authorization, waiver, compliance, or exemption evidence; three remain incomplete. Research-pathway readiness is 9 of 12 proposals.

The program approves only the nine complete proposals and places their extracts behind transfer gates. One incomplete team obtains corrected protocol evidence, one narrows its request to nonidentifying output, and one remains held. The initial denominator and all decisions remain recorded.

Research-disclosure checklist

• Confirm qualified leadership and any delegated decision authority.
• Match recipient, protocol, approval, people, purpose, data, and dates.
• Apply HIPAA research rules when the discloser has that status.
• Justify each patient-identifying field and validate the extract.
• Bind recipient access, redisclosure, security, linkage, and closure duties.
• Stop transfers on expiry, amendment, or unresolved mismatch.
• Reconcile every copy and respond to scope or recipient errors.

Owner controls

The 2024 final rule supplies current alignment. Use leadership delegation, protocol identifiers, recipient qualification, IRB or privacy-board evidence, data minimization, transfer approval, researcher duties, and re-review triggers.

Monitor proposals, pathway type, identifiable fields, approvals, transfers, users, amendments, outputs, expiry, destruction, and incidents. Audit from each research data movement back to the documented determination and from active projects into current recipient and protocol evidence. Retest after policy, EHR, warehouse, transfer, vendor, or research-system changes.